Kappa light chain was present in 74% of the total cohort, with no difference between WM and IgM-MGUS. In the patients diagnosed with WM, the median serum B2M was 2.3 mg/L, median hemoglobin 10 gm/dL, median serum viscosity 1.9 cp, and median platelet count 240 ×109/L.
Forty-one% of the patients with WM required therapy at the time of this study. Results: The median age at diagnosis was 63 years (range, 37–90). The clonal free light chain was considered the involved immunoglobulin free light chain (FLC), whether kappa or lambda. The Freelite assay (The Binding Site, UK) uses antibodies directed against the free light chain (FLC) epitopes. sFLC levels were performed using Freelite™ reagents on a Dade-Behring Nephelometer. Method: We analyzed 159 patients, 99 patients with WM and 70 patients with IgM-MGUS. In this study, we sought to determine the value of serum free light chain (sFLC) in WM. The level of serum beta 2 microglobulin (B2M), cytopenias, and age are poor prognostic markers in WM.
Because of it’s long half-life, it is not a sensitive test for response, indicating the need for more sensitive serum markers that predict tumor burden. The serum IgM level is an important marker of diagnosis and response however, it does not correlate with prognosis. Background: Waldenstrom macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma characterized by the involvement of the bone marrow with lymphoplasmacytic cells and the production of IgM monoclonal protein.
0 kommentar(er)
